Abstract:Quantitative and robust serology assays are critical measurements underpinning global COVID-19 response to diagnostic, surveillance, and vaccine development. Here, we report a proof-of-concept approach for the development of quantitative, multiplexed flow cytometry-based serological and neutralization assays. The serology assays test the IgG and IgM against both the full-length spike antigens and the receptor binding domain (RBD) of the spike antigen. Benchmarking against an RBD-specific SARS-CoV IgG reference standard, the anti-SARS-CoV-2 RBD antibody titer was quantified in the range of 37.6 μg/mL to 31.0 ng/mL. The quantitative assays are highly specific with no correlative cross-reactivity with the spike proteins of MERS, SARS1, OC43 and HKU1 viruses. We further demonstrated good correlation between anti-RBD antibody titers and neutralizing antibody titers. The suite of serology and neutralization assays help to improve measurement confidence and are complementary and foundational for clinical and epidemiologic studies.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop quantitative and standardized serological and neutralizing antibody detection methods in the global response to COVID - 19. Specifically, the paper proposes a multiplex detection method based on flow cytometry for testing IgG and IgM antibodies against the full - length spike antigen of SARS - CoV - 2 and its receptor - binding domain (RBD). By benchmarking against the SARS - CoV - specific RBD reference standard, the paper achieves quantitative determination of SARS - CoV - 2 RBD antibody titers, ranging from 37.6 µg/mL to 31.0 ng/mL. In addition, the paper also shows a good correlation between anti - RBD antibody titers and neutralizing antibody titers, and demonstrates the role of these detection methods in enhancing measurement confidence, which is complementary and fundamental for clinical and epidemiological studies. The key points of the paper include: - **Quantification and Standardization**: Develop quantitative and standardized serological and neutralizing antibody detection methods to support diagnosis, monitoring, and vaccine development. - **Multiplexing**: Use flow cytometry to achieve multiplex detection and test multiple antibodies simultaneously. - **High Sensitivity and Specificity**: Ensure high specificity of the detection methods and avoid cross - reactions with other viruses. - **Neutralizing Antibody Detection**: Develop an alternative neutralizing antibody detection method, using RBD - conjugated microbeads and biotinylated ACE2 protein, which can be completed within a few hours and is suitable for BSL2 laboratories. The development and validation of these methods help to improve the measurement accuracy of SARS - CoV - 2 infection and immune responses, providing important tools for clinical and epidemiological studies.

Towards Quantitative and Standardized Serological and Neutralization Assays for COVID-19